IMCD/€IMCD
1D1W1MYTD1Y5YMAX
Capital at risk
About IMCD
IMCD N.V. specializes in the distribution and formulation of chemicals and ingredients. Founded in 1995 and headquartered in Rotterdam, the Netherlands, the company operates in numerous countries across the world, serving a wide range of industries. IMCD provides value-added services such as technical support, formulation, marketing, and logistics, leveraging its extensive network to deliver tailored solutions that enhance product performance and facilitate innovation.
- Ticker
- €IMCD
- Sector
- Industrials
- Primary listing
- AEX
- Employees
- 5,237
- Headquarters
- Rotterdam, Netherlands
- Website
- www.imcdgroup.com
IMCD Metrics
BasicAdvanced
€5.5B
24.16
€3.90
0.96
€1.81
1.92%
Price and volume
Market cap
€5.5B
Beta
0.96
52-week high
€110.00
52-week low
€68.24
Average daily volume
125K
Dividend rate
€1.81
Financial strength
Current ratio
1.347
Quick ratio
0.851
Long term debt to equity
0.506
Total debt to equity
0.851
Dividend payout ratio (TTM)
46.42%
Interest coverage (TTM)
5.56%
Profitability
EBITDA (TTM)
515.928
Gross margin (TTM)
25.01%
Net profit margin (TTM)
4.63%
Operating margin (TTM)
8.07%
Effective tax rate (TTM)
26.49%
Revenue per employee (TTM)
€950,000
Management effectiveness
Return on assets (TTM)
5.24%
Return on equity (TTM)
11.23%
Valuation
Price to earnings (TTM)
24.157
Price to revenue (TTM)
1.119
Price to book
2.61
Price to tangible book (TTM)
-10.24
Price to free cash flow (TTM)
15.353
Free cash flow yield (TTM)
6.51%
Free cash flow per share (TTM)
6.134
Dividend yield (TTM)
1.92%
Forward dividend yield
1.92%
Growth
Revenue change (TTM)
2.69%
Earnings per share change (TTM)
-14.64%
3-year revenue growth (CAGR)
2.68%
10-year revenue growth (CAGR)
11.37%
3-year earnings per share growth (CAGR)
-8.35%
10-year earnings per share growth (CAGR)
11.51%
3-year dividend per share growth (CAGR)
-8.59%
10-year dividend per share growth (CAGR)
15.19%
What the Analysts think about IMCD
Analyst ratings (Buy, Hold, Sell) for IMCD stock.
Analyst projections of the future price of IMCD stock.
Bulls say / Bears say
IMCD’s first-half recovery was stronger beneath the headline: revenue rose 11% and operating EBITA 8% at constant exchange rates, while free cash flow increased 29% to €222 million. That combination suggests improving demand and good cash conversion. (IMCD)
The growth is becoming more geographically diversified. EMEA revenue and operating EBITA each rose 15% in the first half, while Asia-Pacific revenue grew 14% on a constant-currency basis, helping offset weakness in the Americas. (European Coatings)
IMCD is deepening its technical distribution network rather than simply adding volume. Its expanded Lubrizol partnership gives it authorised access to medical polymers in east China, extending an existing relationship across Europe and North America into a specialist healthcare market. (RubberWorld)
Profitability remains vulnerable to mix and acquisition effects. Gross profit margin fell by 0.7 percentage points to 24.9%, while the Americas reported a 16% decline in operating EBITA, showing that revenue growth is not translating evenly into earnings. (European Coatings)
The main near-term recovery could prove temporary. Reuters reported that JPMorgan expects fading Middle East-related tailwinds, a weaker second half of 2026 and 2027, and structural pressure from Chinese overcapacity and stronger Asian competition. (Reuters)
Demand was still fragile at the start of the year. In the first quarter, constant-currency gross profit rose only 1% and EBITA fell 2%, while management warned that uncertainty and customer confidence remained key risks; this makes the second-half improvement important to sustain. (IMCD, earningscalls.dev)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
IMCD Financial Performance
Revenues and expenses
IMCD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing IMCD
AllEURGBPUSD
Fund name | Fund size | €IMCD weighting |
|---|---|---|
iShares STOXX Europe 600 Chemicals€EXV7 | €104M | 2.64% |
iShares EURO STOXX Mid€DJMC | €572M | 0.67% |
iShares EURO STOXX Mid Cap£DJMC | £491M | 0.67% |
iShares AEX€IAEX | €778M | 0.58% |
iShares AEX£IAEX | £668M | 0.58% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.